Name
CLINICAL PARALLEL 5 - Delta Therapies - Current and Future
Date & Time
Wednesday, March 19, 2025, 3:30 PM - 5:00 PM
Speakers
Maria BUTI, Maria Butí Ferret
Thor Dantas, Federal University of Acre
Pietro Lampertico, University of Milan
Christiane Stern, Center Hospitalier de Versailles
Description
  • Bulevirtide (BLV) as Monotherapy or Combination Treatment with Interferon for Hepatitis Delta Maria Buti
  • Overview of New Drug Development for Hepatitis Delta Pietro Lampertico
  • Management of Delta for indigenous populations Thor Dantas
  • Oral Presentation: EFFICACY AND SAFETY OF BLV MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: POSTTREATMENT RESULTS THROUGH 48 WEEKS AFTER THE END OF TREATMENT FROM AN INTERIM ANALYSIS OF A RANDOMIZED PHASE 3 STUDY MYR301 Pietro Lampertico
  • Oral Presentation: SAFETY AND EFFICACY OF REP 2139-MG IN HEPATITIS D PATIENTS: REPORTING OF EXTENDED FOLLOW-UP DATA FROM THE INTERNATIONAL COMPASSIONATE USE PROGRAM Christiane Stern
  • Q&A